Zaloguj się

Gotowe bibliografie tematyczne / Benign prostatic hyperplasia / Artykuły w czasopismach

Artykuły w czasopismach na temat „Benign prostatic hyperplasia”

Kliknij ten link, aby zobaczyć inne rodzaje publikacji na ten temat: Benign prostatic hyperplasia.

Autor: Grafiati

Data publikacji: 4 czerwca 2021

Data aktualizacji: 1 sierpnia 2024

Utwórz poprawne odniesienie w stylach APA, MLA, Chicago, Harvard i wielu innych

Wybierz rodzaj źródła:

Sprawdź 50 najlepszych artykułów w czasopismach naukowych na temat „Benign prostatic hyperplasia”.

Przycisk „Dodaj do bibliografii” jest dostępny obok każdej pracy w bibliografii. Użyj go – a my automatycznie utworzymy odniesienie bibliograficzne do wybranej pracy w stylu cytowania, którego potrzebujesz: APA, MLA, Harvard, Chicago, Vancouver itp.

Możesz również pobrać pełny tekst publikacji naukowej w formacie „.pdf” i przeczytać adnotację do pracy online, jeśli odpowiednie parametry są dostępne w metadanych.

Przeglądaj artykuły w czasopismach z różnych dziedzin i twórz odpowiednie bibliografie.

1

Leedahl, David D., Phil H. Vo, Pamela M. Maxson i Jenna K. Lovely. "Benign Prostatic Hyperplasia". Journal of Pharmacy Practice 26, nr 1 (13.07.2012): 52–58. http://dx.doi.org/10.1177/0897190012451913.

Pełny tekst źródła

Streszczenie:

This review provides an update on the treatment of benign prostatic hyperplasia and the pharmacologic considerations for perioperative care. By age 85 years, approximately 90% of men have prostate histologic characteristics consistent with benign prostatic hyperplasia. Pharmacologic treatment with an alpha1 receptor antagonist may reduce symptoms and, when given in combination with a 5-alpha-reductase inhibitor, may decrease the risk of urinary retention and the need for surgical intervention. Transurethral resection of the prostate has been the historical standard when surgical intervention is indicated. However, recent evidence suggests that Holmium laser enucleation of the prostate may have similar efficacy with less risk of complications and with decreased catheterization time. Prostatic urological operations may have perioperative complications, including urethral bleeding, acute urinary retention, urinary tract infection, urge incontinence, and venous thromboembolism. Pharmacist recommendations for the appropriate use of laxatives, antibiotics, anticoagulation, and urinary antispasmodics are key components of perioperative management. Surgical interventions improve symptoms but may have complications, providing the pharmacist an opportunity to improve perioperative care.

Style APA, Harvard, Vancouver, ISO itp.

2

Lorenzo, Guillermo, Thomas J. R. Hughes, Pablo Dominguez-Frojan, Alessandro Reali i Hector Gomez. "Computer simulations suggest that prostate enlargement due to benign prostatic hyperplasia mechanically impedes prostate cancer growth". Proceedings of the National Academy of Sciences 116, nr 4 (7.01.2019): 1152–61. http://dx.doi.org/10.1073/pnas.1815735116.

Pełny tekst źródła

Streszczenie:

Prostate cancer and benign prostatic hyperplasia are common genitourinary diseases in aging men. Both pathologies may coexist and share numerous similarities, which have suggested several connections or some interplay between them. However, solid evidence confirming their existence is lacking. Recent studies on extensive series of prostatectomy specimens have shown that tumors originating in larger prostates present favorable pathological features. Hence, large prostates may exert a protective effect against prostate cancer. In this work, we propose a mechanical explanation for this phenomenon. The mechanical stress fields that originate as tumors enlarge have been shown to slow down their dynamics. Benign prostatic hyperplasia contributes to these mechanical stress fields, hence further restraining prostate cancer growth. We derived a tissue-scale, patient-specific mechanically coupled mathematical model to qualitatively investigate the mechanical interaction of prostate cancer and benign prostatic hyperplasia. This model was calibrated by studying the deformation caused by each disease independently. Our simulations show that a history of benign prostatic hyperplasia creates mechanical stress fields in the prostate that impede prostatic tumor growth and limit its invasiveness. The technology presented herein may assist physicians in the clinical management of benign prostate hyperplasia and prostate cancer by predicting pathological outcomes on a tissue-scale, patient-specific basis.

Style APA, Harvard, Vancouver, ISO itp.

3

Dülgeroğlu, Yakup, Gönül Erden, Musa Ekici, Ahmet Yeşilyurt, Öner Odabaş, Fatma Uçar i Gülfer Öztürk. "Diagnostic efficiency of miR-21 and miR-34a serum levels in malign and benign prostate diseases". Yeni Üroloji Dergisi 16, nr 3 (22.10.2021): 221–27. http://dx.doi.org/10.33719/yud.2021;16-3-865045.

Pełny tekst źródła

Streszczenie:

Objective: In this study aimed to determine the diagnostic efficiency of miR-21 and miR-34a serum levels in the discrimination of benign prostatic hyperplasia, chronic prostatitis, and prostate cancer. Materials and Methods: Blood samples were taken from 70 patients (25 benign prostatic hyperplasias, 10 chronic prostatitides, and 35 prostate cancer) who underwent prostate needle biopsy. After obtaining serum under suitable conditions, RNA isolation, cDNA synthesis, and qRT-PCR analysis were performed using Qiagen brand kits on Rotor-Gene® Q (Qiagen, Germany) device. -∆Ct values were calculated using RNU6 as a reference gene for normalization. -∆Ct values were used in all statistical calculations. Results: It was observed that miR-21 serum levels were upregulated in chronic prostatitis and cancer groups compared to benign prostatic hyperplasia and the difference between the groups was statistically significant (p = 0.021 and p = 0.001, respectively). The specificity and sensitivity of miR-21 and miR-21/miR-34a combination was calculated as 56% and 86%; 84% and 71% in discriminating benign prostatic hyperplasia and prostate cancer groups, respectively. Conclusion: In this study, it has been shown that miR-21 and miR-21/miR-34a combination has diagnostic performance that can be a biomarker candidate in diagnosing prostate cancer. In addition, the presence of a gradual increase in chronic prostatitis and prostate cancer at miR-21 levels compared to benign prostatic hyperplasia suggests that inflammation and cancer transformation processes taking place at the molecular level are also reflected in the circulating microRNA profile. Keywords: Prostate cancer, Prostatitis, Benign prostatic hyperplasia, MicroRNA, Diagnostic efficiency

Style APA, Harvard, Vancouver, ISO itp.

4

Al-Bazzaz, Wishyar, Omar Alkhayat i Ali AlKhayat. "Monotherapy versus combination therapy in the treatment of benign prostatic hyperplasia: A single center study". Zanco Journal of Medical Sciences 24, nr 3 (25.12.2020): 333–37. http://dx.doi.org/10.15218/zjms.2020.039.

Pełny tekst źródła

Streszczenie:

Background and objectives: Most benign prostatic hyperplasia patients do not present obvious indicators for surgical intervention, so most of these patients are treated initially with medical therapy. This study aimed to compare the incidence of acute urinary retention after treatment with monotherapy with the incidence after combination therapy and determine the need for surgery in both methods. Methods: This is a retrospective study of the medical records of 248 benign prostatic hyperplasia patients who had attended Rizgary Teaching Hospital from May 2012 to June 2017. These patients were divided into two groups of 138 and 110 patients who have been treated by 0.4 mg tamsulosin capsule once daily and 0.4 mg tamsulosin capsule plus 5mg finasteride tablet once daily, respectively. Benign prostatic hyperplasia outcomes (acute urinary retention, benign prostatic hyperplasia related surgery) were compared between these two groups according to prostate volume and serum prostate specific antigen. Results: The combined treatment had significantly reduced the incidence of acute urinary retention and benign prostatic hyperplasia related surgery than monotherapy (P = 0.006 and 0.044, respectively). Similarly, when prostate volume and prostate specific antigen were above the cutoff value, both acute urinary retention and benign prostatic hyperplasia related surgery were lower in the combination therapy group than the monotherapy group. Conclusion: Combined therapy (0.4 mg tamsulosin plus 5mg finasteride) was significantly superior to 0.4 mg tamsulosin alone in the reduction of the incidence of acute urinary retention and benign prostatic hyperplasia related surgery among benign prostatic hyperplasia patients. Keywords: Benign prostatic hyperplasia; Acute urinary retention; Benign prostatic hyperplasia related surgery; Prostate volume; Prostate specific antigen.

Style APA, Harvard, Vancouver, ISO itp.

5

Rahman, Md A., i H. Naushaba. "Impact of Finasteride on Stroma of Benign Hyperplasia of Prostate". Journal of Medical Science & Research 16, Number 1 (1.01.2011): 3–8. http://dx.doi.org/10.47648/jmsr.2011.v1601.01.

Pełny tekst źródła

Streszczenie:

Benign prostatic hyperplasia (13P11) is a hyperplastic process of the strontal and epithelial cells of the prostate due to effect of male sex hormone testosterone. Testosterone is the main male sex hormone, responsible for growth of sexual character and accessory sex organs. Despite its effectiveness as an male sex hormone, it causes benign prostatic hyperplasia (BM resulting in urinary dysfunction. On the other hand, finasteride. a 4-azastroid, inhibits the hyperplastic effect of testosterone and benign prostatic hyperplasia. The objective of the study was to observe the effects of finasteride on the stroma of testosterone induced prostatic hyperplasis in long Evans rats. This experimental study was carried out in the Department of Anatomy, Sir Salimullah Medical College, Dhaka from January to December 2006. Total 45 matured male long Evans rats of age 8-10 weeks and weighing 200-300 gm were used in this study. They were divided into three equal groups. Group A was vehicle (olive oil) control group, Group 13 was testosterone treated group and Group C was testosterone and finasteride treated group. The rats were sacrificed on the eleventh day. It was concluded that finasteride is an effective drug that successfully inhibits the testosterone induced prostatic hvperplasia.

Style APA, Harvard, Vancouver, ISO itp.

6

Mohammed Ridha Jawad i Ghaith Ali Jasim. "Biochemical and Histopathological evaluation of prostatic tissue under effect of Pterostilbene in benign prostatic hyperplasia rat model". Al Mustansiriyah Journal of Pharmaceutical Sciences 23, nr 2 (23.05.2023): 196–213. http://dx.doi.org/10.32947/ajps.v23i2.1022.

Pełny tekst źródła

Streszczenie:

Background: Benign prostatic hyperplasia [BPH] is the urologic condition that affects elderly men the most frequently Benign prostatic hyperplasia. Benign prostatic hyperplasia must be distinguished from lower urinary tract symptoms and benign prostatic enlargement. which refers to an enlarged prostate, benign prostatic hyperplasia is a purely histological term the development, maintenance, and secretory activity of the prostate and other sex-accessory tissues are stimulated by the presence of certain hormones and growth factors. the pathophysiology of Benign prostatic hyperplasia is significantly influenced by the activity of the enzyme 5α-reductase. It's important to remember that 5-αreductase is responsible for creating Dihydrotestosterone a stronger androgen. Pterostilbene Mostly found in blueberries and grapes and pterostilbene substance with a number of biological properties including anticancer properties. pterostilbene is a lipid-soluble molecule that exists in both cis and trans forms with the latter being more prevalent. The conventional medication for Benign prostatic hyperplasia utilized in this trial was finasteride which inhibits the 5α-reductase enzyme and lowers the amount of Dihydrotestosterone. Methods: Forty-eight male rats were divided into six groups; the control group consisted of eight rats who received subcutaneous injections of oil vehicle for a period of 42 days. The induction group consisted of eight rats who received subcutaneous injections of testosterone propionate for a period of fourteen days. The finasteride group consisted of eight rats who received finasteride 0.44 mg/kg by oral gavage for a period of twenty-eight days following the induction of Benign prostatic hyperplasia and Pterostilbene 200 group included 8 rats were given pterostilbene 200mg/kg by oral gavage for 28 days after 14 days of Benign prostatic hyperplasia induction. pterostilbene 100 group included 8 rats were given a pterostilbene 100mg/kg per day kg by oral gavage for 28 days after 14 days of induction Benign prostatic hyperplasia dose and the resveratrol group included 8 rats were given a resveratrol 100mg/kg per day kg by oral gavage for 28 days after 14 days of induction Benign prostatic hyperplasia After twenty-eight days. Results: Histological section of prostate Pterostilbene 200 were similar those in control negative revealed numerous variable sizes alveoli that filled with homogenous eosinophilic secretion, had normal epithelial and stromal tissue. Conclusion: Pterostilbene have a potent anti-proliferative effect by decrease the hyperplastic nodules for prostate and return epithelial cell to normal and have a very good scavenging activity for free radical [very good as antioxidant] in compare with Vitamin c and resveratrol. Aim of study: evaluate the effect of Pterostilbene as Anti proliferative on Benign prostatic hyperplasia and assess the antioxidant activity for Pterostilbene by DPPH Assay.

Style APA, Harvard, Vancouver, ISO itp.

7

Tang, Ruipeng, i Chuan Xiao. "Correlation between Prostatic Calculi and Benign Prostatic Hyperplasia". Journal of Endocrinology Research 2, nr 1 (6.02.2021): 44. http://dx.doi.org/10.30564/jer.v2i1.2518.

Pełny tekst źródła

Streszczenie:

Prostatic calculus is a common disease of the urinary system, Prostate stones are more common in middle-aged and elderly men, With the development of ultrasonic diagnosis, more and more patients with prostate stone were found in physical examination,According to research shows,The vast majority of patients with benign prostatic hyperplasia in the pathogenesis of examination was found to have prostate stones, but so far the correlation between prostate stones and benign prostatic hyperplasia is still not very clear,Benign prostatic hyperplasia is an important factor affecting the physical and mental health and quality of life of the elderly male, With an increasing trend of population aging in China more quickly, this problem is more and more outstanding, but also allows us to further study the relationship between prostate stones and benign prostatic hyperplasia.

Style APA, Harvard, Vancouver, ISO itp.

8

Roitberg, G. E., V. V. Astashov, K. G. Mkrtchyan i A. A. Lomshakov. "Treatment of beneficial prostate hyperplasia of large sizes: traditional surgical, low-invasive and laser technologies (literature review)". Laser Medicine 24, nr 4 (28.04.2021): 62–68. http://dx.doi.org/10.37895/2071-8004-2020-24-4-62-68.

Pełny tekst źródła

Streszczenie:

Benign prostatic hyperplasia – one of the most common diseases in older men. The treatment strategy for benign prostatic hyperplasia consists in its drug therapy, or active surgical tactics. The indication for planned surgical treatment of benign prostatic hyperplasia is the progression of symptoms of the lower urinary tract, which are not amenable to drug correction. Men with a large prostate volume of more than 80 m3, with severe symptoms of the lower urinary tract, with a history of acute urinary retention episodes, represent a difficult group of patients in terms of choosing the tactics of surgical treatment. This article discusses the most common operations that are used in the treatment of benign prostatic hyperplasia (especially of large sizes): open adenectomy, transurethral resection of the prostate gland, enucleation of benign prostatic hyperplasia using a holmium laser, embolization of an artery of the prostate gland. Surgical treatment of benign prostatic hyperplasia requires an individual approach to the patient, taking into account his age, concomitant pathology and clinical symptoms.

Style APA, Harvard, Vancouver, ISO itp.

9

Kaplan, Steven A. "Benign Prostatic Hyperplasia". Journal of Urology 205, nr 4 (kwiecień 2021): 1199–201. http://dx.doi.org/10.1097/ju.0000000000001612.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

10

Kaplan, Steven A. "Benign Prostatic Hyperplasia". Journal of Urology 205, nr 5 (maj 2021): 1490–92. http://dx.doi.org/10.1097/ju.0000000000001665.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

11

Atan, Ali, Thomas Horn, Frank Hansen, Henrik Jakobsen i Tage Hald. "Benign Prostatic Hyperplasia". Scandinavian Journal of Urology and Nephrology 30, nr 4 (sierpień 1996): 303–6. http://dx.doi.org/10.3109/00365599609182311.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

12

McConnell, John D. "BENIGN PROSTATIC HYPERPLASIA". Urologic Clinics of North America 22, nr 2 (maj 1995): 387–400. http://dx.doi.org/10.1016/s0094-0143(21)00674-1.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

13

Kaplan, Steven A. "Benign Prostatic Hyperplasia". Journal of Urology 205, nr 6 (czerwiec 2021): 1798–800. http://dx.doi.org/10.1097/ju.0000000000001726.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

14

Jønler, Morten, Morten Riehmann i Reginald C. Bruskewitz. "Benign Prostatic Hyperplasia". Drugs 47, nr 1 (styczeń 1994): 66–81. http://dx.doi.org/10.2165/00003495-199447010-00005.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

15

Nunes, Ricardo L. V., Alberto A. Antunes, Antonio Silvinato i Wanderley M. Bernardo. "Benign prostatic hyperplasia". Revista da Associação Médica Brasileira 64, nr 10 (październik 2018): 876–81. http://dx.doi.org/10.1590/1806-9282.64.10.876.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

16

Lovász, Sándor. "Benign prostatic hyperplasia". Orvosi Hetilap 149, nr 11 (1.03.2008): 522–23. http://dx.doi.org/10.1556/oh.2008.28314.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

17

Kaplan, Steven. "Benign Prostatic Hyperplasia". Journal of Urology 207, nr 2 (luty 2022): 441–43. http://dx.doi.org/10.1097/ju.0000000000002318.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

18

Kaplan, Steven. "Benign Prostatic Hyperplasia". Journal of Urology 207, nr 3 (marzec 2022): 710–12. http://dx.doi.org/10.1097/ju.0000000000002368.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

19

Kaplan, Steven A. "Benign Prostatic Hyperplasia". Journal of Urology 206, nr 1 (lipiec 2021): 133–35. http://dx.doi.org/10.1097/ju.0000000000001805.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

20

Tammela, Teuvo. "Benign Prostatic Hyperplasia". Drugs & Aging 10, nr 5 (maj 1997): 349–66. http://dx.doi.org/10.2165/00002512-199710050-00004.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

21

Kaplan, Steven A. "Benign Prostatic Hyperplasia". Journal of Urology 207, nr 1 (styczeń 2022): 201–4. http://dx.doi.org/10.1097/ju.0000000000002275.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

22

Raza, Iffat, Sahrish Mukhtar i Mahrukh Kamran. "BENIGN PROSTATIC HYPERPLASIA;". Professional Medical Journal 24, nr 03 (7.03.2017): 445–52. http://dx.doi.org/10.29309/tpmj/2017.24.03.1557.

Pełny tekst źródła

Streszczenie:

Objectives: To study the effect of anthropometric measures on benign prostatichyperplasia patients in a subset of Karachi population. Study Design: A cross-sectional study.Setting: Ziauddin University Hospital, Radiology Dept, Clifton. Karachi. Method: 103 benignprostatic hyperplasia patients was carried out. These patients were recruited from a urologyclinic. The study subjects were divided on the basis of Age groups, body mass index groupsand waist circumference groups. Result: Mean prostate volume of BPH patients was foundto be was 62.7 ± 12.5 years. Mean BMI was found to 24kg/m2. Mean waist circumferencewas found to be 73.8cms. Prostate volume was found to be doubled in waist circumferenceof greater than 90cm group. Conclusion: Prostate volume greatly enlarges with advancingage. Waist circumference is the only contributing factor among other anthropometric measureswhich causes growth of prostate volume.

Style APA, Harvard, Vancouver, ISO itp.

23

Kaplan, Steven A. "Benign Prostatic Hyperplasia". Journal of Urology 206, nr 3 (wrzesień 2021): 745–47. http://dx.doi.org/10.1097/ju.0000000000001919.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

24

Kaplan, Steven. "Benign Prostatic Hyperplasia". Journal of Urology 207, nr 5 (maj 2022): 1127–28. http://dx.doi.org/10.1097/ju.0000000000002467.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

25

Kaplan, Steven A. "Benign Prostatic Hyperplasia". Journal of Urology 206, nr 2 (sierpień 2021): 447–50. http://dx.doi.org/10.1097/ju.0000000000001854.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

26

Kaplan, Steven. "Benign Prostatic Hyperplasia". Journal of Urology 206, nr 4 (październik 2021): 1038–41. http://dx.doi.org/10.1097/ju.0000000000002125.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

27

Kaplan, Steven. "Benign Prostatic Hyperplasia". Journal of Urology 207, nr 4 (kwiecień 2022): 901–3. http://dx.doi.org/10.1097/ju.0000000000002404.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

28

Kim, Choung Soo. "Benign Prostatic Hyperplasia". Journal of the Korean Medical Association 50, nr 7 (2007): 626. http://dx.doi.org/10.5124/jkma.2007.50.7.626.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

29

Cantlay, Anna, i Holly Ni Raghallaigh. "Benign prostatic hyperplasia". InnovAiT: Education and inspiration for general practice 8, nr 4 (6.03.2015): 238–45. http://dx.doi.org/10.1177/1755738014568038.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

30

Smith, Rick A., Robert Wake i Mark S. Soloway. "Benign prostatic hyperplasia". Postgraduate Medicine 83, nr 6 (maj 1988): 79–85. http://dx.doi.org/10.1080/00325481.1988.11700255.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

31

Moul, Judd W. "Benign prostatic hyperplasia". Postgraduate Medicine 94, nr 6 (listopad 1993): 141–52. http://dx.doi.org/10.1080/00325481.1993.11945750.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

32

Kaplan, Steven A. "Benign Prostatic Hyperplasia". Journal of Urology 170, nr 1 (lipiec 2003): 339–44. http://dx.doi.org/10.1097/00005392-200307000-00090.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

33

Gilchrist, Kathleen. "Benign Prostatic Hyperplasia". Nurse Practitioner 29, nr 6 (czerwiec 2004): 30–37. http://dx.doi.org/10.1097/00006205-200406000-00006.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

34

Melville, A., J. Donovon, T. Sheldon i T. Peters. "Benign prostatic hyperplasia." Quality and Safety in Health Care 5, nr 2 (1.06.1996): 111–19. http://dx.doi.org/10.1136/qshc.5.2.111.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

35

Shabbir, Majid, i Faiz H. Mumtaz. "Benign prostatic hyperplasia". Journal of the Royal Society for the Promotion of Health 124, nr 5 (wrzesień 2004): 222–27. http://dx.doi.org/10.1177/146642400412400519.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

36

KRING, DARIA. "Benign prostatic hyperplasia". Nursing 33, nr 5 (maj 2003): 44–45. http://dx.doi.org/10.1097/00152193-200305000-00046.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

37

Parnham, Arie, i Ahsanul Haq. "Benign prostatic hyperplasia". Journal of Clinical Urology 6, nr 1 (styczeń 2013): 24–31. http://dx.doi.org/10.1177/2051415812473243.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

38

Rosario, Derek J., i Richard Bryant. "Benign Prostatic Hyperplasia". Surgery (Oxford) 20, nr 11 (listopad 2002): 268–72. http://dx.doi.org/10.1383/surg.20.11.268.14541.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

39

McNicholas, Tom, i Stephen Mitchell. "Benign prostatic hyperplasia". Surgery (Oxford) 24, nr 5 (maj 2006): 169–72. http://dx.doi.org/10.1383/surg.2006.24.5.169.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

40

Kendall, A. Richard, i Barry S. Stein. "Benign prostatic hyperplasia". Postgraduate Medicine 77, nr 5 (kwiecień 1985): 166–75. http://dx.doi.org/10.1080/00325481.1985.11698957.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

41

Kaplan, Steven A. "Benign Prostatic Hyperplasia". Journal of Urology 205, nr 1 (styczeń 2021): 279–81. http://dx.doi.org/10.1097/ju.0000000000001455.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

42

Kaplan, Steven A. "Benign Prostatic Hyperplasia". Journal of Urology 205, nr 2 (luty 2021): 603–5. http://dx.doi.org/10.1097/ju.0000000000001493.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

43

Kaplan, Steven A. "Benign Prostatic Hyperplasia". Journal of Urology 185, nr 5 (maj 2011): 1819. http://dx.doi.org/10.1016/j.juro.2011.01.063.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

44

Kaplan, Steven A. "Benign Prostatic Hyperplasia". Journal of Urology 185, nr 5 (maj 2011): 1818. http://dx.doi.org/10.1016/j.juro.2011.01.064.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

45

Kaplan, Steven A. "Benign Prostatic Hyperplasia". Journal of Urology 186, nr 3 (wrzesień 2011): 1152. http://dx.doi.org/10.1016/j.juro.2011.05.034.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

46

McNicholas, Tom, i Stephen Mitchell. "Benign prostatic hyperplasia". Surgery (Oxford) 26, nr 5 (maj 2008): 218–22. http://dx.doi.org/10.1016/j.mpsur.2008.04.007.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

47

McNicholas, Tom, i Daniel Swallow. "Benign prostatic hyperplasia". Surgery (Oxford) 29, nr 6 (czerwiec 2011): 282–86. http://dx.doi.org/10.1016/j.mpsur.2011.03.005.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

48

Thiruchelvam, Nikesh. "Benign prostatic hyperplasia". Surgery (Oxford) 32, nr 6 (czerwiec 2014): 314–22. http://dx.doi.org/10.1016/j.mpsur.2014.04.006.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

49

Jonler, Morten, Morten Riehmann, Runa Brinkmann i Reginald C. Bruskewitz. "Benign Prostatic Hyperplasia". Endocrinology and Metabolism Clinics of North America 23, nr 4 (grudzień 1994): 795–807. http://dx.doi.org/10.1016/s0889-8529(18)30068-9.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

50

Clarke, Harry S. "Benign Prostatic Hyperplasia". American Journal of the Medical Sciences 314, nr 4 (październik 1997): 239–44. http://dx.doi.org/10.1016/s0002-9629(15)40207-1.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

Oferujemy zniżki na wszystkie plany premium dla autorów, których prace zostały uwzględnione w tematycznych zestawieniach literatury. Skontaktuj się z nami, aby uzyskać unikalny kod promocyjny!